21 News and views: Exciting new approaches in therapy, double-hit therapies, JAK inhibitors
Objectives. Discuss the different mechanisms of action of belimumab and anifrolumab and their roles in modulating immune pathways in SLE .Explain the clinical indications, efficacy data, and trial outcomes (BLISS and TULIP studies) of BEL and ANI in systemic lupus erythematosus .Apply clinical reasoning to choose between BEL and ANI based on patient phenotype, disease activity, and safety considerations
Authors
- Murray Urowitz
Institutions
- University of Toronto (CA)
Publication Details
- Journal
- Abstracts
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/lupus-2025-la.21
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00